Levomethadone Hydrochloride Molteni

Levomethadone hydrochloride, the active ingredient in Levomethadone Hydrochloride Molteni, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the management of opioid dependence and severe chronic pain in adult patients. GNH USA supplies Levomethadone Hydrochloride Molteni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone Hydrochloride is an opioid agonist used in the treatment of conditions related to opioid receptors and severe pain.

- Opioid dependence: helps maintain abstinence and reduces cravings. - Severe chronic pain: provides long‑acting analgesia for patients with persistent pain. - Opioid withdrawal management: alleviates withdrawal symptoms during detoxification.

Levomethadone Hydrochloride may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Constipation - Dizziness - Drowsiness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Seizures - Severe hypotension - Allergic reactions (e.g., rash, angioedema) - Adrenal insufficiency

When prescribing Levomethadone Hydrochloride, clinicians should consider several safety measures. - Assess respiratory function: monitor for signs of depression, especially during initiation. - Monitor liver function: adjust use in hepatic impairment. - Evaluate history of substance misuse: consider risk of dependence. - Avoid concomitant CNS depressants: limit additive sedation. - Adjust dose in renal impairment: use caution in reduced clearance. - Store at room temperature: keep in the original container, protect from moisture.

Levomethadone Hydrochloride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other central nervous system depressants (e.g., benzodiazepines, barbiturates). - Monoamine oxidase inhibitors (MAOIs). - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Concurrent opioid analgesics. - Alcohol consumption.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine). - Serotonergic agents (risk of serotonin syndrome). - Antihistamines that cause sedation. - Diuretics that may affect electrolyte balance. - Other QT‑prolonging drugs.